Lightning Round: Recursion Pharmaceuticals and NuScale Power

Stock Analysis & Investment Recommendations - A caller discusses a stock they bought a year and a half ago that has been consistently dropping after earnings reports, but believes it will turn around [2] - The caller mentions the company received $30 million from Roach Genante in October and has $785 million in cash [2] - A major announcement regarding drug trials is expected on December 8th, which the caller anticipates will be favorable [2] - Nat Khan, described as a genius, will take over Recursion Pharmaceuticals on January 1st, with expectations of a banner year in 2026 [3] - The host acknowledges the stock's "horrendous" performance and categorizes it as speculative, advising caution despite the company's financial resources [3][4] - Regarding New Scale Power SMR in the nuclear sector, the recommendation is to scale out on the way up, selling portions at $25, $27, and $30, and eventually getting rid of all of it [5] Company & Industry Specifics - GE Vernova is highlighted as a company that knows how to build nuclear power plants [5] - Five Below is mentioned as a bargain retailer undergoing a turnaround, with an analysis to determine if the company can sustain its performance or if the price is too high [6] Program Information - The Lightning Round is sponsored by Charles Schwab [6] - Viewers are encouraged to follow Jim Kramer on X (formerly Twitter), and can send questions via Twitter using madmentions, email to madmoney@cnbc.com, or call 1-800-743-CNBC [6] - Missed segments can be found at madmoney.cnbc.com [7]